The effectiveness of tetragonola honey combinations Aff.biroi and royal jelly as immunomodulators : immunomodulators modelling in facing the plague of COVID-19
COVID-19 epidemic caused serious concern around the world. Innate and adaptive immunity prevents occurring acute infection. Immunomodulatory activity tests and increased leucocyte cells in rat have been carried out using honey (H) and royal jelly (RJ). This study aims to prove the combination of honey and royal jelly in increasing the leucocyte profile in male Sprague Dawley rats. This study used 28 rats divided into 7 groups, namely the negative control and positive, single dose group H and single dose RJ and the combination dose 1, dose 2, and dose 3, then on day the 8th and 11th rats were injected intraperitoneally with 2% sheep red blood cell antigen as much as 0.5 ml. Leucocyte profile were carried out on the 8th and 15th days. The results showed significant difference on leukocyte count (p = 0.000), but there was a decrease in the normal range on day 15th. The highest leucocyte count was showed on the honey and the combination 3 group. Leukocyte differential showed no significant difference (p> 0.05). The honey group and the dose combination 3 showed an increase in the number of segment neutrophils. The difference in lymphocyte reduction was seen between the honey and royal jelly group, with the dose combination 3, respectively. There are significant differences in granulocyte cells enhancement between the honey group and the dose combination 3. We concluded that single dose honey can be an immunomodulatory. Dose combination 3 can be an alternative for further research for immunomodulatory supplement product.